XTX Topco Ltd Buys New Shares in Cerus Co. (NASDAQ:CERS)

XTX Topco Ltd bought a new stake in Cerus Co. (NASDAQ:CERS) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 150,368 shares of the biotechnology company’s stock, valued at approximately $265,000. XTX Topco Ltd owned 0.08% of Cerus at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wasatch Advisors LP lifted its holdings in Cerus by 11.2% during the 4th quarter. Wasatch Advisors LP now owns 6,530,019 shares of the biotechnology company’s stock worth $14,105,000 after buying an additional 656,971 shares during the last quarter. Hood River Capital Management LLC purchased a new stake in Cerus during the 1st quarter worth about $566,000. Easterly Investment Partners LLC purchased a new stake in Cerus during the 1st quarter worth about $405,000. Nikko Asset Management Americas Inc. lifted its holdings in Cerus by 2.4% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 7,750,700 shares of the biotechnology company’s stock worth $14,571,000 after buying an additional 182,629 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Cerus by 2.4% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock worth $14,649,000 after buying an additional 182,629 shares during the last quarter. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Richard J. Benjamin sold 21,605 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total value of $54,012.50. Following the completion of the sale, the insider now directly owns 438,007 shares of the company’s stock, valued at approximately $1,095,017.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at $1,286,995.70. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

Cerus Stock Down 1.7 %

Shares of NASDAQ CERS opened at $1.75 on Friday. The company has a market capitalization of $323.56 million, a price-to-earnings ratio of -10.29 and a beta of 1.19. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The business has a 50-day moving average of $2.13 and a two-hundred day moving average of $1.94. Cerus Co. has a 1 year low of $1.21 and a 1 year high of $2.59.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $45.08 million during the quarter, compared to the consensus estimate of $42.50 million. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. During the same period in the previous year, the business earned ($0.07) EPS. On average, analysts forecast that Cerus Co. will post -0.13 earnings per share for the current fiscal year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.